Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin
2006; Oxford University Press; Volume: 27; Issue: 9 Linguagem: Inglês
10.1093/eurheartj/ehi754
ISSN1522-9645
AutoresSteen Husted, Håkan Emanuelsson, Stan Heptinstall, Per Morten Sandset, Mark Wickens, Gary Peters,
Tópico(s)Acute Myocardial Infarction Research
ResumoAims This double-blind, parallel-group study was conducted to assess the pharmacodynamics, pharmacokinetics, and safety of AZD6140, the first oral, reversible adenosine diphosphate (ADP) receptor antagonist.
Referência(s)